Abstract
Alzheimer’s disease (AD) is an expanding health and socioeconomic concern in industrialized societies, and the leading cause of intellectual impairment in our aging population. The cause of AD remains unknown, and there are currently no effective treatments to stop or reverse the progression of this uniquely human and age-related neurological disorder. Elucidation of the AD mechanism and factors that contribute to the initiation, progression, and spreading of this chronic and fatal neurodegeneration will ultimately result in improved and effective diagnostics and therapeutic strategies.
microRNAs (miRNAs) comprise a relatively recently discovered category of 20–24 nucleotide non-coding RNAs that function post-transcriptionally in shaping the transcriptome of the cell, and in doing so, contribute to the molecular-genetics and phenotype of human CNS health and disease. To date about 2550 unique mature human miRNAs have been characterized, however only highly selected miRNA populations appear to be enriched in different anatomical compartments within the CNS.
This general commentary for the ‘Special Issue: 40th Year of Neurochemical Research’ will bring into perspective (i) some very recent findings on the extraordinary biophysics and signaling properties of CNS miRNA in AD and aging human brain; (ii) how specific intrinsic biophysical attributes of miRNAs may play defining roles in the establishment, proliferation and spreading of the AD phenotype; and (iii) how miRNAs can serve as prospective therapeutic targets and biomarkers potentially useful in the clinical management of this terminal neurological disease whose incidence in our rapidly aging population is reaching epidemic proportions.
Similar content being viewed by others
References
Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T (2001) Identification of novel genes coding for small expressed RNAs. Science 294(5543):853–858
Lee RC, Ambros V (2001) An extensive class of small RNAs in Caenorhabditis elegans. Science 294(5543):862–864
Lau NC, Lim LP, Weinstein EG, Bartel DP (2001) An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science 294(5543):858–862
Lukiw WJ (2007) MiRNA speciation in fetal, adult and Alzheimer’s disease hippocampus. NeuroReport 18:297–300
Schipper HM, Maes OC, Chertkow HM, Wang E (2007) MicroRNA expression in Alzheimer blood mononuclear cells. Gene Regul Syst Biol 1:263–274
Cogswell JP, Ward J, Taylor IA, Waters M, Shi Y, Cannon B, Kelnar K, Kemppainen J, Brown D, Chen C, Prinjha RK, Richardson JC, Saunders AM, Roses AD, Richards CA (2008) Identification of miRNA changes in Alzheimer’s brain and CSF yields putative biomarkers and insights into disease pathways. J Alzheimers Dis 14:27–41
http://www.mirbase.org/; http://www.mirbase.org/blog/2014/03/high-confidence-micrornas/
Alexandrov PN, Dua P, Lukiw WJ (2014) Up-regulation of miRNA-146a in progressive, age-related inflammatory neurodegenerative disorders of the human CNS. Front Neurol 5:181. doi:10.3389/fneur.2014.00181
Clement C, Hill JM, Dua P, Culicchia F, Lukiw WJ (2015) Analysis of RNA from Alzheimer’s disease post-mortem brain tissues. Mol Neurobiol. doi:10.1007/s12035-015-9105-6
Schmidt U, Keck ME, Buell DR (2015) miRNAs and other non-coding RNAs in posttraumatic stress disorder: a systematic review of clinical and animal studies. J Psychiatr Res 65:1–8. doi:10.1016/j.jpsychires.2015.03.014
Lukiw WJ (2013) Variability in microRNA (miRNA) abundance, speciation and complexity amongst different human populations and potential relevance to AD. Front Cell Neurosci 7:133. doi:10.3389/fncel.2013.00133
Zhao Y, Bhattacharjee S, Dua P, Alexandrov PN, Lukiw WJ (2015) microRNA-based biomarkers and the diagnosis of Alzheimer’s disease. Front Neurol 6:162. doi:10.3389/fneur.2015.00162
Codocedo JF, Ríos JA, Godoy JA, Inestrosa NC (2015) Are microRNAs the molecular link between metabolic syndrome and Alzheimer’s disease? Mol Neurobiol. doi:10.1007/s12035-015-9201-7
Femminella GD, Ferrara N, Rengo G (2015) The emerging role of microRNAs in Alzheimer’s disease. Front Physiol 6:40. doi:10.3389/fphys.2015.00040
Cogoni C, Ruberti F, Barbato C (2015) MicroRNA landscape in Alzheimer’s disease. CNS Neurol Disord Drug Targets 14:168–175
Pogue AI, Clement C, Hill JM, Lukiw WJ (2014) Evolution of microRNA (miRNA) Structure and function in plants and animals: relevance to aging and disease. J Aging Sci. doi:10.4172/2329-8847.1000119
Pogue AI, Hill JM, Lukiw WJ (2014) MicroRNA (miRNA): sequence and stability, viroid-like properties, and disease association in the CNS. Brain Res 1584:73–79. doi:10.1016/j.brainres.2014.03.042
Tan L, Yu JT, Tan L (2015) Causes and consequences of microRNA dysregulation in neurodegenerative diseases. Mol Neurobiol 51:1249–1262. doi:10.1007/s12035-014-8803-9
Bekris LM, Leverenz JB (2015) The biomarker and therapeutic potential of miRNA in Alzheimer’s disease. Neurodegener Dis Manag 5:61–74. doi:10.2217/nmt.14.52
Zafari S, Backes C, Meese E, Keller A (2015) Circulating biomarker panels in Alzheimer’s disease. Gerontology. doi:10.1159/000375236
Sethi P, Lukiw WJ (2009) Micro-RNA abundance and stability in human brain: specific alterations in Alzheimer’s disease temporal lobe neocortex. Neurosci Lett 459:100–104. doi:10.1016/j.neulet.2009.04.052
Sanei M, Chen X (2015) Mechanisms of microRNA turnover. Curr Opin Plant Biol 27:199–206. doi:10.1016/j.pbi.2015.07.008
Bertoia ML, Bertrand KA, Sawyer SJ, Rimm EB, Mukamal KJ (2015) Reproducibility of circulating microRNAs in stored plasma samples. PLoS ONE 10:e0136665. doi:10.1371/journal.pone.0136665
Lee YS, Lee JA, Kaang BK (2015) Regulation of mRNA stability by ARE-binding proteins in synaptic plasticity. Neurobiol Learn Mem. doi:10.1016/j.nlm.2015.08.004
McCaskill J, Praihirunkit P, Sharp PM, Buck AH (2015) RNA-mediated degradation of microRNAs: a widespread viral strategy? RNA Biol 12:579–585. doi:10.1080/15476286.2015.1034912
Shen T, Han M, Wei G, Ni T (2015) An intriguing RNA species-perspectives of circularized RNA. Protein Cell. doi:10.1007/s13238-015-0202-0
Ebbesen KK, Kjems J, Hansen TB (2015) Circular RNAs: identification, biogenesis and function. Biochim Biophys Acta. doi:10.1016/j.bbagrm.2015.07.007
Lukiw WJ, Surjyadipta B, Dua P, Alexandrov PN (2012) Common microRNAs target complement factor H (CFH) regulation in Alzheimer’s disease and in age-related macular degeneration. Int J Biochem Mol Biol 3:105–116
Hill JM, Zhao Y, Bhattacharjee S, Lukiw WJ (2014) miRNAs and viroids utilize common strategies in genetic signal transfer. Front Mol Neurosci 7:10. doi:10.3389/fnmol.2014.00010
Tan Z, Zhang W, Shi Y, Wang F (2015) RNA folding: structure prediction, folding kinetics and ion electrostatics. Adv Exp Med Biol 827:143–183. doi:10.1007/978-94-017-9245-5_11
Hill JM, Lukiw WJ (2014) Comparing miRNAs and viroids; highly conserved molecular mechanisms for the transmission of genetic information. Front Cell Neurosci 8:45. doi:10.3389/fncel.2014.00045
Hill JM, Clement C, Zhao Y, Lukiw WJ (2015) Induction of the pro-inflammatory NF-kB-sensitive miRNA-146a by human neurotrophic viruses. Front Microbiol 6:43. doi:10.3389/fmicb.2015.00043
Hill JM, Clement C, Pogue AI, Bhattacharjee S, Zhao Y, Lukiw WJ (2014) Pathogenic microbes, the microbiome, and Alzheimer’s disease (AD). Front Aging Neurosci 6:127. doi:10.3389/fnagi.2014.00127
Pogue AI, Hill JM, Lukiw WJ (2014) MicroRNA (miRNA): sequence and stability, viroid-like properties, and disease association in the CNS. Brain Res 1584:73–79. doi:10.1016/j.brainres.2014.03.042
Gago-Zachert S (2015) Viroids, infectious long non-coding RNAs with autonomous replication. Virus Res. doi:10.1016/j.virusres.2015.08.018
Petkovic S, Müller S (2015) RNA circularization strategies in vivo and in vitro. Nucleic Acids Res 43:2454–2465. doi:10.1093/nar/gkv045
Hill JM, Dua P, Clement C, Lukiw WJ (2014) An evaluation of progressive amyloidogenic and pro-inflammatory change in the primary visual cortex and retina in Alzheimer’s disease (AD). Front Neurosci 8:347. doi:10.3389/fnins.2014.00347
Roth W, Hecker D, Fava E (2016) Systems biology approaches to the study of biological networks underlying Alzheimer’s disease: role of miRNAs. Methods Mol Biol 1303:349–377. doi:10.1007/978-1-4939-2627-5_21
Acknowledgments
Sincere thanks are extended to Drs. L. Carver, E. Head, W. Poon, H. LeBlanc, F. Culicchia, C. Eicken and C. Hebel for short post-mortem interval (PMI) human brain and/or retinal tissues or extracts, miRNA array work and initial data interpretation, and to D Guillot and AI Pogue for expert technical assistance. Thanks are also extended to the many neuropathologists, physicians and researchers of Canada and the US who have provided high quality, short post-mortem interval (PMI) human CNS and retinal tissues or extracted brain and retinal total and fractionated RNA for scientific study. Research on miRNA in the Lukiw laboratory involving the innate-immune response in AD, AMD and in other forms of neurological or retinal disease, amyloidogenesis and neuro-inflammation was supported through an unrestricted grant to the LSU Eye Center from Research to Prevent Blindness (RPB); the Louisiana Biotechnology Research Network (LBRN) and NIH Grants NEI EY006311, NIA AG18031 and NIA AG038834.
Author information
Authors and Affiliations
Corresponding author
Additional information
This work was presented in part at the Society for Neuroscience (SFN) Annual Meeting 15–19 November 2014, Washington, USA and at the Association for Research in Vision and Ophthalmology (ARVO) Annual conference 3–7 May 2015 in Denver CO USA.
Special Issue: 40th Year of Neurochemical Research.
Rights and permissions
About this article
Cite this article
Hill, J.M., Lukiw, W.J. microRNA (miRNA)-Mediated Pathogenetic Signaling in Alzheimer’s Disease (AD). Neurochem Res 41, 96–100 (2016). https://doi.org/10.1007/s11064-015-1734-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11064-015-1734-7